Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884)
Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin’s lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinbla...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2005-11, Vol.63 (4), p.1184-1190 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1190 |
|---|---|
| container_issue | 4 |
| container_start_page | 1184 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 63 |
| creator | Aleman, Berthe M.P. Girinsky, Théodore van der Maazen, Richard W.M. Strijk, Simon Meijnders, Paul Bortolus, Roberto Olofsen-van Acht, Manouk J.J. Lybeert, Marnix L.M. Lievens, Yolande Eghbali, Houchingue Noordijk, Evert M. Tomšič, Radka Meerwaldt, Jacobus H. Poortmans, Philip M.P. Smit, Wilma G.J.M. Pinna, Antonella Henry-Amar, Michel Raemaekers, John M.M. |
| description | Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin’s lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy.
Methods and Materials: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16–24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose |
| doi_str_mv | 10.1016/j.ijrobp.2005.03.044 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20022559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301605005791</els_id><sourcerecordid>20022559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-d3b0559fe9e909323456fcfd0a65c0c0a191dcdf81781f205958fff0f48a08033</originalsourceid><addsrcrecordid>eNp9kM1qGzEURkVJaJy0b1CCVqFdzPRqNBqPNoVg0qQQCCkOZCdk_cRyZkZTSXbxLq-R1-uTVMaG7LK6i3u-73IPQl8IlARI831VulXwi7GsAFgJtIS6_oAmpJ3ygjL2eIQmQBsoaIZP0GmMKwAgZFp_RCeEcdoQNp2g5_u17FzaYuWHFHyHvcVu2PhuY3Rhnek0DlI7n5YmyHGbd3iUyZkhRfzXpSWWeiMHZTS-8frp2Q3_Xl4j7rb9uPS9xF-v7n7PZ7iCtq2_fULHVnbRfD7MM_Tw82o-uylu765_zS5vC0U5SYWmC2CMW8MNB04rWrPGKqtBNkyBAkk40UrblkxbYitgnLXWWrB1K6EFSs_Qxb53DP7P2sQkeheV6To5GL-OIgurqnwhg_UeVMHHGIwVY3C9DFtBQOwki5XYS95lmAAqsuQcOz_0rxe90W-hg9UM_NgDJn-5cSaIqLKybMkFo5LQ3r1_4T8-YZBs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20022559</pqid></control><display><type>article</type><title>Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884)</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Aleman, Berthe M.P. ; Girinsky, Théodore ; van der Maazen, Richard W.M. ; Strijk, Simon ; Meijnders, Paul ; Bortolus, Roberto ; Olofsen-van Acht, Manouk J.J. ; Lybeert, Marnix L.M. ; Lievens, Yolande ; Eghbali, Houchingue ; Noordijk, Evert M. ; Tomšič, Radka ; Meerwaldt, Jacobus H. ; Poortmans, Philip M.P. ; Smit, Wilma G.J.M. ; Pinna, Antonella ; Henry-Amar, Michel ; Raemaekers, John M.M.</creator><creatorcontrib>Aleman, Berthe M.P. ; Girinsky, Théodore ; van der Maazen, Richard W.M. ; Strijk, Simon ; Meijnders, Paul ; Bortolus, Roberto ; Olofsen-van Acht, Manouk J.J. ; Lybeert, Marnix L.M. ; Lievens, Yolande ; Eghbali, Houchingue ; Noordijk, Evert M. ; Tomšič, Radka ; Meerwaldt, Jacobus H. ; Poortmans, Philip M.P. ; Smit, Wilma G.J.M. ; Pinna, Antonella ; Henry-Amar, Michel ; Raemaekers, John M.M. ; European Organization for Research ; Treatment of Cancer (EORTC) Lymphoma Group</creatorcontrib><description>Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin’s lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy.
Methods and Materials: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16–24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose <90% of the prescribed dose.
Results: Of the 739 patients who were enrolled in the trial between 1989 and 2000, 57% achieved a CR; 152 of 172 patients randomized to IFRT actually received radiotherapy; and in 135 patients, quality control was performed. The overall major violation rate was 47%, predominantly concerning target volumes. The total dose was correct in 81% of the patients. After a median follow-up of 6.5 years, there was no difference in cumulative failure rate between patients with or without major violations. There was no relationship between incidence or site of relapse and major protocol violations.
Conclusion: In advanced-stage HL patients in complete remission after six to eight cycles of MOPP-ABV, the outcome was not influenced by violation of the radiotherapy protocol.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2005.03.044</identifier><identifier>PMID: 15936157</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Advanced Hodgkin’s lymphoma ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bleomycin ; Bleomycin - administration & dosage ; Chemotherapy ; Clinical trials ; Combined Modality Therapy ; Combined modality treatment ; Data processing ; Doxorubicin - administration & dosage ; Hodgkin Disease - drug therapy ; Hodgkin Disease - pathology ; Hodgkin Disease - radiotherapy ; Hodgkin's disease ; Humans ; Lymphatic Irradiation - standards ; Mechlorethamine ; Mechlorethamine - administration & dosage ; Prednisone - administration & dosage ; procarbazine ; Procarbazine - administration & dosage ; Quality assurance ; Quality Control ; Radiation ; Radiotherapy ; Radiotherapy Dosage ; Randomized Controlled Trials as Topic ; Remission ; Remission Induction ; Retrospective Studies ; Vinblastine ; Vinblastine - administration & dosage ; Vincristine ; Vincristine - administration & dosage]]></subject><ispartof>International journal of radiation oncology, biology, physics, 2005-11, Vol.63 (4), p.1184-1190</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-d3b0559fe9e909323456fcfd0a65c0c0a191dcdf81781f205958fff0f48a08033</citedby><cites>FETCH-LOGICAL-c391t-d3b0559fe9e909323456fcfd0a65c0c0a191dcdf81781f205958fff0f48a08033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2005.03.044$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15936157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aleman, Berthe M.P.</creatorcontrib><creatorcontrib>Girinsky, Théodore</creatorcontrib><creatorcontrib>van der Maazen, Richard W.M.</creatorcontrib><creatorcontrib>Strijk, Simon</creatorcontrib><creatorcontrib>Meijnders, Paul</creatorcontrib><creatorcontrib>Bortolus, Roberto</creatorcontrib><creatorcontrib>Olofsen-van Acht, Manouk J.J.</creatorcontrib><creatorcontrib>Lybeert, Marnix L.M.</creatorcontrib><creatorcontrib>Lievens, Yolande</creatorcontrib><creatorcontrib>Eghbali, Houchingue</creatorcontrib><creatorcontrib>Noordijk, Evert M.</creatorcontrib><creatorcontrib>Tomšič, Radka</creatorcontrib><creatorcontrib>Meerwaldt, Jacobus H.</creatorcontrib><creatorcontrib>Poortmans, Philip M.P.</creatorcontrib><creatorcontrib>Smit, Wilma G.J.M.</creatorcontrib><creatorcontrib>Pinna, Antonella</creatorcontrib><creatorcontrib>Henry-Amar, Michel</creatorcontrib><creatorcontrib>Raemaekers, John M.M.</creatorcontrib><creatorcontrib>European Organization for Research</creatorcontrib><creatorcontrib>Treatment of Cancer (EORTC) Lymphoma Group</creatorcontrib><title>Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884)</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin’s lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy.
Methods and Materials: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16–24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose <90% of the prescribed dose.
Results: Of the 739 patients who were enrolled in the trial between 1989 and 2000, 57% achieved a CR; 152 of 172 patients randomized to IFRT actually received radiotherapy; and in 135 patients, quality control was performed. The overall major violation rate was 47%, predominantly concerning target volumes. The total dose was correct in 81% of the patients. After a median follow-up of 6.5 years, there was no difference in cumulative failure rate between patients with or without major violations. There was no relationship between incidence or site of relapse and major protocol violations.
Conclusion: In advanced-stage HL patients in complete remission after six to eight cycles of MOPP-ABV, the outcome was not influenced by violation of the radiotherapy protocol.</description><subject>Advanced Hodgkin’s lymphoma</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bleomycin</subject><subject>Bleomycin - administration & dosage</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Combined modality treatment</subject><subject>Data processing</subject><subject>Doxorubicin - administration & dosage</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin Disease - radiotherapy</subject><subject>Hodgkin's disease</subject><subject>Humans</subject><subject>Lymphatic Irradiation - standards</subject><subject>Mechlorethamine</subject><subject>Mechlorethamine - administration & dosage</subject><subject>Prednisone - administration & dosage</subject><subject>procarbazine</subject><subject>Procarbazine - administration & dosage</subject><subject>Quality assurance</subject><subject>Quality Control</subject><subject>Radiation</subject><subject>Radiotherapy</subject><subject>Radiotherapy Dosage</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Vinblastine</subject><subject>Vinblastine - administration & dosage</subject><subject>Vincristine</subject><subject>Vincristine - administration & dosage</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1qGzEURkVJaJy0b1CCVqFdzPRqNBqPNoVg0qQQCCkOZCdk_cRyZkZTSXbxLq-R1-uTVMaG7LK6i3u-73IPQl8IlARI831VulXwi7GsAFgJtIS6_oAmpJ3ygjL2eIQmQBsoaIZP0GmMKwAgZFp_RCeEcdoQNp2g5_u17FzaYuWHFHyHvcVu2PhuY3Rhnek0DlI7n5YmyHGbd3iUyZkhRfzXpSWWeiMHZTS-8frp2Q3_Xl4j7rb9uPS9xF-v7n7PZ7iCtq2_fULHVnbRfD7MM_Tw82o-uylu765_zS5vC0U5SYWmC2CMW8MNB04rWrPGKqtBNkyBAkk40UrblkxbYitgnLXWWrB1K6EFSs_Qxb53DP7P2sQkeheV6To5GL-OIgurqnwhg_UeVMHHGIwVY3C9DFtBQOwki5XYS95lmAAqsuQcOz_0rxe90W-hg9UM_NgDJn-5cSaIqLKybMkFo5LQ3r1_4T8-YZBs</recordid><startdate>20051115</startdate><enddate>20051115</enddate><creator>Aleman, Berthe M.P.</creator><creator>Girinsky, Théodore</creator><creator>van der Maazen, Richard W.M.</creator><creator>Strijk, Simon</creator><creator>Meijnders, Paul</creator><creator>Bortolus, Roberto</creator><creator>Olofsen-van Acht, Manouk J.J.</creator><creator>Lybeert, Marnix L.M.</creator><creator>Lievens, Yolande</creator><creator>Eghbali, Houchingue</creator><creator>Noordijk, Evert M.</creator><creator>Tomšič, Radka</creator><creator>Meerwaldt, Jacobus H.</creator><creator>Poortmans, Philip M.P.</creator><creator>Smit, Wilma G.J.M.</creator><creator>Pinna, Antonella</creator><creator>Henry-Amar, Michel</creator><creator>Raemaekers, John M.M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20051115</creationdate><title>Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884)</title><author>Aleman, Berthe M.P. ; Girinsky, Théodore ; van der Maazen, Richard W.M. ; Strijk, Simon ; Meijnders, Paul ; Bortolus, Roberto ; Olofsen-van Acht, Manouk J.J. ; Lybeert, Marnix L.M. ; Lievens, Yolande ; Eghbali, Houchingue ; Noordijk, Evert M. ; Tomšič, Radka ; Meerwaldt, Jacobus H. ; Poortmans, Philip M.P. ; Smit, Wilma G.J.M. ; Pinna, Antonella ; Henry-Amar, Michel ; Raemaekers, John M.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-d3b0559fe9e909323456fcfd0a65c0c0a191dcdf81781f205958fff0f48a08033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Advanced Hodgkin’s lymphoma</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bleomycin</topic><topic>Bleomycin - administration & dosage</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Combined modality treatment</topic><topic>Data processing</topic><topic>Doxorubicin - administration & dosage</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin Disease - radiotherapy</topic><topic>Hodgkin's disease</topic><topic>Humans</topic><topic>Lymphatic Irradiation - standards</topic><topic>Mechlorethamine</topic><topic>Mechlorethamine - administration & dosage</topic><topic>Prednisone - administration & dosage</topic><topic>procarbazine</topic><topic>Procarbazine - administration & dosage</topic><topic>Quality assurance</topic><topic>Quality Control</topic><topic>Radiation</topic><topic>Radiotherapy</topic><topic>Radiotherapy Dosage</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Vinblastine</topic><topic>Vinblastine - administration & dosage</topic><topic>Vincristine</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aleman, Berthe M.P.</creatorcontrib><creatorcontrib>Girinsky, Théodore</creatorcontrib><creatorcontrib>van der Maazen, Richard W.M.</creatorcontrib><creatorcontrib>Strijk, Simon</creatorcontrib><creatorcontrib>Meijnders, Paul</creatorcontrib><creatorcontrib>Bortolus, Roberto</creatorcontrib><creatorcontrib>Olofsen-van Acht, Manouk J.J.</creatorcontrib><creatorcontrib>Lybeert, Marnix L.M.</creatorcontrib><creatorcontrib>Lievens, Yolande</creatorcontrib><creatorcontrib>Eghbali, Houchingue</creatorcontrib><creatorcontrib>Noordijk, Evert M.</creatorcontrib><creatorcontrib>Tomšič, Radka</creatorcontrib><creatorcontrib>Meerwaldt, Jacobus H.</creatorcontrib><creatorcontrib>Poortmans, Philip M.P.</creatorcontrib><creatorcontrib>Smit, Wilma G.J.M.</creatorcontrib><creatorcontrib>Pinna, Antonella</creatorcontrib><creatorcontrib>Henry-Amar, Michel</creatorcontrib><creatorcontrib>Raemaekers, John M.M.</creatorcontrib><creatorcontrib>European Organization for Research</creatorcontrib><creatorcontrib>Treatment of Cancer (EORTC) Lymphoma Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aleman, Berthe M.P.</au><au>Girinsky, Théodore</au><au>van der Maazen, Richard W.M.</au><au>Strijk, Simon</au><au>Meijnders, Paul</au><au>Bortolus, Roberto</au><au>Olofsen-van Acht, Manouk J.J.</au><au>Lybeert, Marnix L.M.</au><au>Lievens, Yolande</au><au>Eghbali, Houchingue</au><au>Noordijk, Evert M.</au><au>Tomšič, Radka</au><au>Meerwaldt, Jacobus H.</au><au>Poortmans, Philip M.P.</au><au>Smit, Wilma G.J.M.</au><au>Pinna, Antonella</au><au>Henry-Amar, Michel</au><au>Raemaekers, John M.M.</au><aucorp>European Organization for Research</aucorp><aucorp>Treatment of Cancer (EORTC) Lymphoma Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884)</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2005-11-15</date><risdate>2005</risdate><volume>63</volume><issue>4</issue><spage>1184</spage><epage>1190</epage><pages>1184-1190</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin’s lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy.
Methods and Materials: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16–24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose <90% of the prescribed dose.
Results: Of the 739 patients who were enrolled in the trial between 1989 and 2000, 57% achieved a CR; 152 of 172 patients randomized to IFRT actually received radiotherapy; and in 135 patients, quality control was performed. The overall major violation rate was 47%, predominantly concerning target volumes. The total dose was correct in 81% of the patients. After a median follow-up of 6.5 years, there was no difference in cumulative failure rate between patients with or without major violations. There was no relationship between incidence or site of relapse and major protocol violations.
Conclusion: In advanced-stage HL patients in complete remission after six to eight cycles of MOPP-ABV, the outcome was not influenced by violation of the radiotherapy protocol.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15936157</pmid><doi>10.1016/j.ijrobp.2005.03.044</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2005-11, Vol.63 (4), p.1184-1190 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20022559 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Advanced Hodgkin’s lymphoma Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin Bleomycin - administration & dosage Chemotherapy Clinical trials Combined Modality Therapy Combined modality treatment Data processing Doxorubicin - administration & dosage Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin Disease - radiotherapy Hodgkin's disease Humans Lymphatic Irradiation - standards Mechlorethamine Mechlorethamine - administration & dosage Prednisone - administration & dosage procarbazine Procarbazine - administration & dosage Quality assurance Quality Control Radiation Radiotherapy Radiotherapy Dosage Randomized Controlled Trials as Topic Remission Remission Induction Retrospective Studies Vinblastine Vinblastine - administration & dosage Vincristine Vincristine - administration & dosage |
| title | Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A59%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20control%20of%20involved-field%20radiotherapy%20in%20patients%20with%20advanced%20Hodgkin%E2%80%99s%20lymphoma%20(EORTC%2020884)&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Aleman,%20Berthe%20M.P.&rft.aucorp=European%20Organization%20for%20Research&rft.date=2005-11-15&rft.volume=63&rft.issue=4&rft.spage=1184&rft.epage=1190&rft.pages=1184-1190&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2005.03.044&rft_dat=%3Cproquest_cross%3E20022559%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20022559&rft_id=info:pmid/15936157&rft_els_id=S0360301605005791&rfr_iscdi=true |